Neumora Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMRA research report →
About the company
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder.
- CEO
- Daljit Singh Aurora
- IPO
- 2023
- Employees
- 110
- HQ
- Watertown, DE, US
Price Chart
- Market Cap
- $309.42M
- P/E
- -1.26
- P/S
- 0.00
- P/B
- 4.25
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -181.70%
- ROIC
- -179.83%
- Revenue
- $0 · 0.00%
- Net Income
- $-236,928,000 · 2.81%
- EPS
- $-1.45 · 5.23%
- Op Income
- $-241,156,000
- FCF YoY
- -12.85%
- 52W High
- $3.65
- 52W Low
- $0.79
- 50D MA
- $1.84
- 200D MA
- $2.19
- Beta
- 2.76
- Avg Volume
- 2.29M
Get TickerSpark's AI analysis on NMRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | Burow Kristina | other | 80,000 |
| May 27, 26 | Fust Matthew K | other | 80,000 |
| May 27, 26 | Piacquad David | other | 80,000 |
| May 27, 26 | Halawa Alaa | other | 80,000 |
| May 27, 26 | Ho Maykin | other | 80,000 |
| Feb 17, 26 | Aurora Daljit Singh | sell | 6,165 |
| Feb 17, 26 | Pinto Joshua | sell | 5,967 |
| Feb 17, 26 | BERNS PAUL L | sell | 9,819 |
| Feb 17, 26 | Milligan Michael Lee | sell | 1,436 |
| Jan 8, 26 | Milligan Michael Lee | other | 350,000 |
Our NMRA coverage
Recent articles, reports, and earnings notes.
No research on NMRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NMRA report →Similar companies
Peers in the same neighborhood.